Combination of Radioligand Therapy and Immunotherapy: How to Make It Work in Clinic?
Rubin Jiao, Ekaterina Dadachova College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, CanadaCorrespondence: Ekaterina Dadachova, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Bld, Room B18, Saskatoon, SK, S7N 5E5, Canada, Tel...
Saved in:
| Main Authors: | Jiao R, Dadachova E |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/combination-of-radioligand-therapy-and-immunotherapy-how-to-make-it-wo-peer-reviewed-fulltext-article-ITT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Update on DOTA-Peptides PET Imaging and Potential Advancements of Radioligand Therapy in Intracranial Meningiomas
by: Viviana Benfante, et al.
Published: (2025-04-01) -
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia
by: Moritz B. Bastian, et al.
Published: (2025-07-01) -
‘Cell knife’ for cancer: the clinician’s perspective
by: Zihan Zhou, et al.
Published: (2025-04-01) -
Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy
by: Jonatan Dewulf, et al.
Published: (2024-12-01) -
The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01)